Iron preparations in the treatment of anemia in cancer patients

Snegovoĭ A.V.

doi:https://doi.org/

Snegovoĭ A.V.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Iron preparations in the treatment of anemia in cancer patients

Authors:

Snegovoĭ A.V.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2012;1(2): 114‑116

Read: 39691 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Snegovoĭ AV. Iron preparations in the treatment of anemia in cancer patients. P.A. Herzen Journal of Oncology. 2012;1(2):114‑116. (In Russ.)

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Use of HIFU therapy in combination with monochemotherapy in a patient with locally advanced adenogenic pancreatic cancer and impaired functional status. P.A. Herzen Journal of Oncology. 2025;(3):83-88

Evaluation of the skeletal muscle index in predicting toxic complications of antitumor drug therapy in patients with gastric cancer. P.A. Herzen Journal of Oncology. 2025;(4):29-36

Small cell carcinoma of the parotid gland. P.A. Herzen Journal of Oncology. 2025;(4):69-74

The effect of the iron III polysaccharide complex use on the cytokines, natriuretic peptide and erythropoietin levels in patients with chronic heart failure accompanied with anemia. Russian Journal of Preventive Medicine. 2025;(3):80-86

Iron supplements and erythropoiesis-stimulating agents in intensive care of postpartum hemorrhage: a Bayesian network meta-analysis. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):59-67

What we have to change in the treatment of ST-segment elevation myocardial infarction?. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):183-190

Differential diagnosis of anemia in ulcerative colitis: a clinical case. Russian Journal of Evidence-Based Gastroenterology. 2025;(2):115-120

Erythrocyte indices — markers for the diagnosis of blood iron deficiency in donors. Russian Journal of Preventive Medicine. 2025;(6):88-91

A review of the recent clinical studies on the treatment of patients with the chronic kidney disease et advanced stages. Russian Journal of Preventive Medicine. 2025;(8):110-114

Results of comprehensive geriatric evaluation in outpatients over 65 years old depending on the presence of anemia. Subanalysis of the EVKALIPT study. Russian Journal of Preventive Medicine. 2025;(9):101-111

Abstract:

The paper considers the problem of anemia in cancer patients. Iron deficiency is one of the causes of anemia. Absolute or functional iron deficiency lowers the efficacy of recombinant erythropoietin used to treat anemia with induced chemotherapy. Numerous trials have shown that intravenous versus oral iron preparations are more effective in compensating for the lack of iron indispensable for optimal erythropoiesis. Today's American and European guidelines (ESMO, NCCN) for the treatment of anemia in cancer patients include the compulsory use of intravenous iron formulations.

Keywords:

anemia

chemotherapy

iron-deficiency anemia

erythropoiesis

Authors:

Snegovoĭ A.V.

FGBU "Rossiĭskiĭ onkologicheskiĭ nauchnyĭ tsentr im. N.N. Blokhina" RAMN, Moskva

Close metadata

References:

Ludwig H., Van Bells S., Barret-Lee P. et al. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur. J. Cancer. 2004; 40: 2293-306.
Caro J.J., Salas M., Ward A. et al. Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer. 2001; 91: 2214-21.
Khorana A., Francis C., Blumberg N. et al. Blood transfusions, thrombosis and mortality in hospitalized patients with cancer. Arch. Intern. Med. 2008; 168: 2377-81.
Bohlius J., Wilson J., Seidenfeld J. et al. Recombinant human erythropoietins and cancer patients: update meta-analysis of 57 studies including 9353 patients. J. Natl. Cancer Inst. 2006; 98: 708-14.
Abramov M.E. Anemiya na fone khimioterapii. Puti korrektsii. Farmateka. 2012; 8: 50-4.
Ptushkin V.V. Anemiya v onkologii: podkhody k lecheniyu. Sovremennaya onkologiya. 2012; 14 (1): 58-63.
Aapro M., Osterborg A., Gasco P. et al. Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v.iron. Ann. Oncol. 2012. doi: 10.1093/annonc/mds112.
Pavlov A.D., Morshchakova E.F., Rumyantseva A.G. Anemiya pri zlokachestvennykh novoobrazovaniyakh: patogenez i lechenie rekombinantnymi chelovecheskim eritropoetinom. Sovremennaya onkologiya. 2002; 4: 50-4.
Dührsen U., Augener W., Zwingers T., Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. Br. J. Haematol. 1987; 67 (2): 235-9.
De Rienzo D.P., Saleem A. Anemia of chronic disease: a review of pathogenesis. Tex. Med. 1990; 86: 80-3.
Krause A., Neitz S., Magert H. et al. LEAP-1, a novel highly disulde-bonded human peptide, exhibits antimicrobial activity. FEBS Letters. 2000; 480: 147-50.
Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol. Chem. 2001; 276: 7806-10.
Milovanov Yu.S., Milovanova L.Yu., Kozlovskaya L.V. Nefrogennaya anemiya: patogenez, prognosticheskoe znachenie, printsipy lecheniya. Klinicheskaya nefrologiya. 2010; 6: 7-18.
Dvoretskii L.I. Zhelezodefitsitnaya anemiya v praktike terapevta. Russkii meditsinskii zhurnal. 2009; 23: 1517-21.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines). Cancer- and chemotherapy-induced Anemia. Version 2.2012 (R).www.NCCN.org.
Crichton R., Danielson G., Geisser P. Iron therapy with special emphasis on intravenous administration. Science. 2008; 1-127.
Auerbach M., Ballard H., Trout R. et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-label, randomized trial. J. Clin. Oncol. 2004; 22: 1301-7.
Henry D.H., Dahl N.V., Auerbach M. et al. Intravenous ferric gluconate improves response to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy. Oncologist. 2007; 12: 231-42.
Bastit L., Vandebroek A., Altintas S. et al. Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J. Clin. Oncol. 2008; 26: 1611-8.
Pedrazzoli P., Farris A., Del Prete S. et al. Randomized trial of intravenous iron supplementation in patients with chemotherapy- related anemia without iron deficiency treated with darbepoetin alfa. J. Clin. Oncol. 2008; 26: 1619-25.
Hedenus M., Birgegard G., Nasman P. et al. Addition of intravenous iron to epoetin beta increases hemoglobin response and decreases epoetin dose requirement in anemic patients with lymphoproliferative malignancies: a randomized multicenter study. Leukemia. 2007; 21: 627-32.
Dangsuwan P., Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol. Oncol. 2010; 116 (3): 522-25.
Steinmetz T., Tschechne B., Virgin G. Ferric Carboxymaltose for the Correction of Cancer- and Chemotherapy-Induced Anaemia in Clinical Practice. J. Support Cancer Care. 2010; 19: 261.
Schrijvers D., de Samblanx H., Roila F. Erythropoiesis-stimulating agents in the treatment of anaemia in cancer patients: ESMO Clinical Practice Guidelines for use. Ann. Oncol. 2010; 21: S 5: v244-v247, doi: 10.1093/annonc/mdq202.